This study is to see if the medicine TARPEYO® helps adults with a kidney problem called IgA nephropathy after 9 months of treatment. IgA nephropathy is a disease that affects the kidneys by causing inflammation and reducing their ability to filter waste. Participants who have already taken TARPEYO® for 9 months will continue for 19 more months with different doses to see if it helps further. They will take TARPEYO® in 16 mg, 8 mg, and 4 mg doses over this time. During the study, participants will have urine and blood tests and physical exams.
- The study lasts about 19 months.
- Participants will need regular medical tests and exams.
- Participants must have stable doses of certain medications before starting.
People who have had other kidney diseases, kidney transplants, or certain medical conditions cannot join. Pregnant women or those planning to become pregnant, and those taking certain drugs, are also not eligible. It's important to be willing to follow all study rules if you want to participate.